Refuge Biotechnologies

Refuge Biotechnologies operates as a preclinical-stage cancer immunotherapy company, founded in 2015. The company was established by a team that includes Dr. Bing C. Wang, who served as CEO, and Dr. Stanley Qi, a scientific founder from Stanford University whose work is central to the company's technological platform. Dr. Qi, a prominent bioengineer, pioneered the development of a nuclease-deactivated Cas9 (dCas9). This modified CRISPR system functions not as molecular scissors to cut DNA, but as a precise tool to either activate (CRISPRa) or interfere with (CRISPRi) gene expression. This innovation allows for the turning on or off of specific genes without making permanent alterations to the genetic code. Dr. Wang, a cancer survivor, brought nearly a decade of life science investment banking experience to the company, having served as a director at Barclays Capital.

The company's business model focuses on developing its proprietary cell therapies and forming strategic partnerships with larger pharmaceutical entities. A key milestone was the exclusive, worldwide license agreement announced in October 2022 with Kite, a Gilead Company. Under this agreement, Kite gained exclusive rights to use Refuge's gene expression platform to develop treatments for blood cancers, taking on all related R&D, manufacturing, and commercialization costs. In return, Refuge received an upfront payment and is eligible for performance-based milestone payments, while retaining all rights for programs related to solid tumor indications. The company has also engaged in collaborations, such as a 2021 agreement with The University of Texas MD Anderson Cancer Center to co-develop its RB-340 CAR T cell therapy and apply its platform to MD Anderson's tumor-infiltrating lymphocyte (TIL) programs.

Refuge Biotechnologies develops intelligent cell therapies, primarily CAR-T, designed to combat cancer more effectively. The core of its approach is the receptor-dCas platform, which engineers immune cells to sense their environment and react selectively. These therapeutic cells can be programmed to recognize specific antigens on cancer cells. Upon detection, the cells conditionally activate or repress multiple genes simultaneously. For example, a therapy could be designed to down-regulate the PD-1 gene—a common checkpoint inhibitor—only when the T-cell is near a tumor, thereby reducing T-cell exhaustion and increasing its cancer-fighting persistence specifically at the tumor site. This context-dependent system aims to create more potent treatments with fewer toxic side effects compared to first-generation cell therapies. While the company has explored treatments for both blood cancers and solid tumors, the recent partnership with Kite has delineated a focus, with Kite pursuing blood cancers and Refuge retaining solid tumor applications.

Keywords: cancer immunotherapy, cell therapy, synthetic biology, CRISPRi, CRISPRa, CAR-T, gene expression, dCas9, solid tumors, biologics development